Clinical Outcomes and Patient Profiles in the UK Medical Cannabis Registry: A k-Means Clustering Analysis.
| Journal | Journal of clinical pharmacology |
| Study Type | Cohort |
| Population | Human participants |
This represents one of the largest longitudinal analyses of medical cannabis outcomes to date, providing real-world evidence on treatment response patterns over 24 months. The clustering approach identifies distinct patient phenotypes that may guide clinical decision-making and patient selection.
This cohort study analyzed 8,945 patients from the UK Medical Cannabis Registry using k-means clustering to identify distinct health-related quality of life trajectories over 24 months. Patients completed validated outcome measures including EQ-5D-5L, GAD-7, and sleep quality scales at multiple timepoints. The clustering analysis revealed distinct response patterns, with regression modeling identifying baseline predictors of treatment outcomes. This registry-based approach provides real-world evidence of cannabis-based medicinal product efficacy across diverse patient populations and conditions.
“While registry data has inherent limitations compared to randomized controlled trials, this scale of longitudinal follow-up provides valuable insights into treatment durability and patient phenotyping. I find the clustering approach particularly useful for identifying which patients are most likely to benefit from cannabis therapy.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What does this study tell us about patient response patterns to medical cannabis treatment?
This large registry study of 8,945 patients used advanced clustering analysis to identify distinct response patterns in health-related quality of life over 24 months. The research reveals that patients fall into different response trajectories, suggesting that medical cannabis efficacy varies significantly between patient subgroups rather than showing uniform effects across all users.
How long should patients expect to wait before seeing improvements in quality of life with medical cannabis?
The study tracked patients at multiple time points from 1 month to 24 months, providing real-world evidence of when improvements typically occur. While specific timing details aren’t provided in the summary, the longitudinal design suggests that meaningful changes in quality of life, anxiety, and sleep can be measured and tracked over both short-term (1-6 months) and long-term (12-24 months) periods.
Can we predict which patients are most likely to benefit from cannabis-based medicinal products?
Yes, the researchers identified baseline predictors that can help determine which patients are more likely to fall into favorable response clusters. This predictive modeling approach could help clinicians better select appropriate candidates for medical cannabis therapy and set realistic expectations for treatment outcomes.
What specific outcomes were measured to assess medical cannabis effectiveness?
The study used validated clinical scales including the EQ-5D-5L for quality of life, GAD-7 for anxiety symptoms, and the Single-Item Sleep Quality Scale. These standardized measures provide objective, clinically meaningful data that can guide treatment decisions and allow for comparison with other therapeutic interventions.
How does this registry data address the current evidence gap in medical cannabis research?
This study provides much-needed real-world evidence from a large patient cohort over an extended follow-up period, addressing the noted “paucity of high-quality evidence” in medical cannabis research. The registry design captures actual clinical practice outcomes rather than controlled trial conditions, offering valuable insights into how cannabis-based medicinal products perform in routine healthcare settings.
